Previous research has indicated that CKS2 is significantly upregulated in tumors like NSCLC and breast cancer, serving as a potential biomarker for tumor diagnosis or treatment (Wan et al. 2022; Huang et al. 2019). This evidence concerns the gene CKS2 and breast carcinoma.